Bibliographic Details
| Title: |
Statement on safety of cannabidiol as a novel food: data gaps and uncertainties |
| Authors: |
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Rosangela Marchelli, Monika Neuhäuser‐Berthold, Morten Poulsen, Miguel Prieto Maradona, Josef Rudolf Schlatter, Viviana Trezza, Henk van Loveren, Océane Albert, Céline Dumas, Andrea Germini, Wolfgang Gelbmann, Georges Kass, Eirini Kouloura, Estefania Noriega Fernandez, Annamaria Rossi, Helle Katrine Knutsen |
| Source: |
EFSA Journal, Vol 20, Iss 6, Pp n/a-n/a (2022) |
| Publisher Information: |
Wiley, 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Nutrition. Foods and food supply
LCC:Chemical technology |
| Subject Terms: |
Cannabidiol, Novel Food, safety, data gaps, Nutrition. Foods and food supply, TX341-641, Chemical technology, TP1-1185 |
| More Details: |
Abstract The European Commission has determined that cannabidiol (CBD) can be considered as a novel food (NF), and currently, 19 applications are under assessment at EFSA. While assessing these, it has become clear that there are knowledge gaps that need to be addressed before a conclusion on the safety of CBD can be reached. Consequently, EFSA has issued this statement, summarising the state of knowledge on the safety of CBD consumption and highlighting areas where more data are needed. Literature searches for both animal and human studies have been conducted to identify safety concerns. Many human studies have been carried out with Epidyolex®, a CBD drug authorised to treat refractory epilepsies. In the context of medical conditions, adverse effects are tolerated if the benefit outweighs the adverse effect. This is, however, not acceptable when considering CBD as a NF. Furthermore, most of the human data referred to in the CBD applications investigated the efficacy of Epidyolex (or CBD) at therapeutic doses. No NOAEL could be identified from these studies. Given the complexity and importance of CBD receptors and pathways, interactions need to be taken into account when considering CBD as a NF. The effects on drug metabolism need to be clarified. Toxicokinetics in different matrices, the half‐life and accumulation need to be examined. The effect of CBD on liver, gastrointestinal tract, endocrine system, nervous system and on psychological function needs to be clarified. Studies in animals show significant reproductive toxicity, and the extent to which this occurs in humans generally and in women of child‐bearing age specifically needs to be assessed. Considering the significant uncertainties and data gaps, the Panel concludes that the safety of CBD as a NF cannot currently be established. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1831-4732 |
| Relation: |
https://doaj.org/toc/1831-4732 |
| DOI: |
10.2903/j.efsa.2022.7322 |
| Access URL: |
https://doaj.org/article/80cc46d65c6b457bad84fbddf7eb4498 |
| Accession Number: |
edsdoj.80cc46d65c6b457bad84fbddf7eb4498 |
| Database: |
Directory of Open Access Journals |
